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Summary
Background Infectious complications and associated mortality are a major concern in acute pancreatitis. Enteral 
administration of probiotics could prevent infectious complications, but convincing evidence is scarce. Our aim was 
to assess the eﬀ  ects of probiotic prophylaxis in patients with predicted severe acute pancreatitis.
Methods In this multicentre randomised, double-blind, placebo-controlled trial, 298 patients with predicted severe 
acute pancreatitis (Acute Physiology and Chronic Health Evaluation [APACHE II] score ≥8, Imrie score ≥3, or 
C-reactive protein >150 mg/L) were randomly assigned within 72 h of onset of symptoms to receive a multispecies 
probiotic preparation (n=153) or placebo (n=145), administered enterally twice daily for 28 days. The primary endpoint 
was the composite of infectious complications—ie, infected pancreatic necrosis, bacteraemia, pneumonia, urosepsis, 
or infected ascites—during admission and 90-day follow-up. Analyses were by intention to treat. This study is 
registered, number ISRCTN38327949.
Findings One person in each group was excluded from analyses because of incorrect diagnoses of pancreatitis; thus, 
152 individuals in the probiotics group and 144 in the placebo group were analysed. Groups were much the same at 
baseline in terms of patients’ characteristics and disease severity. Infectious complications occurred in 46 (30%) patients 
in the probiotics group and 41 (28%) of those in the placebo group (relative risk 1·06, 95% CI 0·75–1·51). 24 (16%) 
patients in the probiotics group died, compared with nine (6%) in the placebo group (relative risk 2·53, 95% CI 
1·22–5·25). Nine patients in the probiotics group developed bowel ischaemia (eight with fatal outcome), compared 
with none in the placebo group (p=0·004).
Interpretation In patients with predicted severe acute pancreatitis, probiotic prophylaxis with this combination of 
probiotic strains did not reduce the risk of infectious complications and was associated with an increased risk of 
mortality. Probiotic prophylaxis should therefore not be administered in this category of patients.
Introduction
The incidence of acute pancreatitis in Europe and the 
USA is increasing by about 5% per year, mainly owing to 
an increase in biliary pancreatitis.
1–3 About a ﬁ  fth  of 
patients will develop necrotising pancreatitis, which is 
associated with a 10–30% mortality rate, mostly attributed 
to infectious complications and infection of 
(peri)pancreatic necrotic tissue in particular.
1 These 
infections are thought to be the sequelae of a cascade of 
events starting with small-bowel bacterial overgrowth, 
mucosal barrier failure, and a pro  inﬂ  ammatory response 
leading to bacterial translocation of intestinal bacteria.
4–6 
Systemic antibiotic prophylaxis has long been studied as 
a measure to prevent secondary infection in acute 
pancreatitis.
1 However, two double-blind, placebo-
controlled trials
7,8 and two meta-analyses
9,10 have failed to 
show a beneﬁ  cial  eﬀ   ect, and many clinicians have 
abandoned this strategy. In the two antibiotic trials, the 
incidence of extrapancreatic infections (eg, bacteraemia, 
pneumonia) and pancreatic infection remained high.
7,8 
Con  sequently, there is a clear need for other strategies to 
prevent infectious complications in patients with acute 
pancreatitis.
Probiotics, as an adjunct to enteral nutrition, have raised 
high expectations and are currently gaining worldwide 
popularity for their presumed health-promoting eﬀ  ects.
11,12 
Certain strains of probiotic bacteria might prevent 
infectious complications by reducing small-bowel bacterial 
overgrowth, restoring gastro  intestinal barrier function, 
and modulating the immune system.
11,12 A reduction of 
infectious compli  cations has been reported in several 
clinical studies with probiotics in patients undergoing 
elective abdominal operations
13,14 and in patients with acute 
pancreatitis.
15 However, because of their small size and 
methodological quality, these studies do not justify global 
implementation of probiotics as a preventive measure in 
acute pancreatitis. Accordingly, we embarked on a nation-
wide multicentre randomised, double-blind, placebo-
controlled trial—the PRObiotics in PAncreatitis TRIAl 
(PROPATRIA)—to assess the eﬀ  ects of probiotic pro  phyl-
axis in patients with predicted severe acute pancreatitis.
Methods
Patients
The design and rationale of the study have been described 
in detail elsewhere.
16 Adult patients admitted with a ﬁ  rst 
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episode of acute pancreatitis were enrolled in eight 
university medical centres and seven major teaching 
hospitals in the Netherlands. Acute pancreatitis was 
deﬁ  ned as abdominal pain in combination with serum 
amylase or lipase concentrations that were raised to at least 
three times the institutional upper limit of normal. Patients 
were not enrolled in the study if any of the following 
criteria were present: pancreatitis after endoscopic 
retrograde cholangiopancreaticography; suspected malig-
nancy of the pancreas or biliary tree; non-pancreatic 
infection or sepsis caused by a second disease; diagnosis of 
pancreatitis ﬁ  rst made at operation; or a medical history of 
immune deﬁ  ciency.
Patients with acute pancreatitis and an Acute Physiology 
and Chronic Health Evaluation (APACHE II) score of 8 or 
more,
17 Imrie/modiﬁ  ed Glasgow score of 3 or more,
18 or 
C-reactive protein over 150 mg/L,
19 predicting a severe 
course of disease, were eligible for randomisation.
All patients or their legal representatives gave written 
informed consent. This study was investigator-initiated 
and investigator-driven and done in accordance with the 
principles of the Declaration of Helsinki and good clinical 
practice guidelines. The institutional review board of each 
participating hospital approved the protocol.
Procedures
Randomisation was done with a computer-generated 
permuted-block sequence and balanced by participating 
centre and by presumed cause (biliary vs non-biliary) in 
blocks of four. Patients were randomly assigned to receive 
either a multispecies probiotic preparation or a placebo 
twice daily at the ﬁ  rst possible occasion, but no later than 
72 h after onset of symptoms of pancreatitis.
The study was double-blinded. Both the probiotic and 
placebo preparations were packaged in identical, numbered 
sachets that were stored in identical, numbered containers. 
The study product and placebo were both white powders, 
identical in weight, smell, and taste. All doctors, nurses, 
research staﬀ  , and patients involved remained unaware of 
the actual product administered during the entire study 
period. An independent monitoring committee was 
informed in cases of serious adverse events that were 
possibly associated with the study product. At the time of a 
prespeciﬁ  ed interim analysis,
16 the monitoring committee 
advised about whether to continue the trial.
The rationale for the design of the multispecies probiotic 
preparation has been described in detail elsewhere.
20 In 
brief, the study product (Ecologic 641, Winclove Bio In-
dustries, Amsterdam, Netherlands) consisted of six dif-
ferent strains of freeze-dried, viable bacteria: Lactobacillus 
acidophilus, Lactobacillus casei, Lactobacillus salivarius, 
Lactococcus lactis, Biﬁ  dobacterium  biﬁ  dum, and Biﬁ  do-
bacterium lactis (previously classiﬁ  ed  as  Biﬁ  dobacterium 
infantis), in a total daily dose of 10¹⁰ bacteria, plus corn-
starch and maltodextrins. The individual probiotic cultures 
are sold by major probiotic producers as ingredients for 
probiotic supplements or dairy food and carry the European 
Union qualiﬁ  ed presumption of safety (QPS). Individual 
strains were selected on the basis of their capacity to inhibit 
growth of pathogens most often cultured from infected 
necro  tising pancreatitis in vitro.
20,21 Probiotic species that 
were ever reported to have been associated with an infec-
tious complication, irrespective of underlying disease, were 
excluded.
20 Placebo sachets contained only cornstarch and 
maltodextrins. Both the probiotic and placebo prepar  ations 
were checked according to national regu  lations for any 
contamination with known pathogens and for the pres  ence 
of endotoxins. Three diﬀ  erent batches of pro  biotics and 
placebo were produced, tested, and used during the study.
After randomisation, each patient had a nasojejunal 
feeding tube inserted. The study product or placebo was 
administered twice daily and added to the continuously 
running ﬁ  bre-enriched tube feeding (Nutrison Multi Fibre, 
Nutricia, Zoetermeer, Netherlands). The study product or 
placebo was dissolved in sterilised distilled water and 
administered for a maximum of 28 days. If placement of 
the nasojejunal tube was delayed for more than 12 h, the 
ﬁ  rst dose of the study product or placebo was taken orally. 
Nasojejunal tubes were placed either by upper 
gastrointestinal endoscopy or under ﬂ  uoroscopic guidance. 
When nasojejunal tubes became blocked or were pulled 
out, a new tube was re-inserted at the ﬁ  rst  possible 
opportunity, generally within 24 h. The amount of tube 
feeding was gradually increased over the ﬁ  rst days with an 
energy target of 125 kJ/kg (up to 90 kg) on day 4 after start 
of enteral nutrition. When patients started oral intake, the 
nasojejunal tube was removed and the study product or 
placebo was dissolved in tap water and ingested orally for 
the remainder of the 28 days. Administration of the study 
product or placebo was stopped when a patient was 
diagnosed with infected pancreatic necrosis. Patients 
discharged before 28 days were only allowed to stop 
treatment if CT showed the absence of pancreatic necrosis 
or ﬂ  uid collection. During the study, patients were not 
allowed to use any commercially available product 
containing probiotics. During administration of the study 
product or placebo, nursing staﬀ   recorded the number of 
sachets administered and registered any potential 
side-eﬀ  ect (eg, abdominal complaints).
Antibiotic prophylaxis was not given routinely in patients 
with necrotising pancreatitis. The use of antibiotics was 
recorded, irrespective of indication. When endoscopic 
retrograde cholangiopancreaticography was indicated in 
cases of biliary pancreatitis, antibiotic prophylaxis was 
allowed. A standard baseline (intravenous) contrast-
enhanced CT scan was done 7 days after admission to 
detect pancreatic necrosis. One experienced radiologist 
(TLB), unaware of treatment allocation, re-read all CT 
scans to assess the CT severity index.
22 In cases of a clear 
clinical diagnosis of infected (peri)pancreatic necrosis 
(persistent fever and clinical deterioration in the third or 
fourth week of disease in the presence of documented 
necrosis or air bubbles in the collections with necrosis on 
CT, while other sources of infection were absent), 
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ﬁ  ne-needle aspiration of (peri)pancreatic collections was 
not mandatory to conﬁ  rm the clinical suspicion. A positive 
culture was mandatory for the endpoint of infected 
necrosis. During surgical intervention or percutaneous 
drainage for (suspected or documented) infected necrosis, 
tissue or ﬂ  uid samples were sent for routine microbiological 
assessment. Body temperature was measured at least twice 
daily and, in cases of fever, blood cultures were drawn. 
Further diagnostic and therapeutic measures were left to 
the treating clinicians’ discretion.
The primary endpoint was the composite of any of the 
following infectious complications: infected pancreatic 
necrosis, bacteraemia, pneumonia, urosepsis, or infected 
ascites, during admission and 90-day follow-up (panel). All 
infections were weighted equally; multiple infections in 
the same patient were deemed to be one endpoint. 
Secondary endpoints (during admission and 90-day 
follow-up) were mortality, sequential organ failure 
assessment (SOFA) scores, (multi)organ failure during 
admission, onset of (multi)organ failure after 
randomisation, need for surgical intervention because of 
(documented or suspected) infected necrosis or 
intra-abdominal catastrophe, hospital stay, intensive-care 
stay, use of antibiotics, and abdominal complaints (nausea 
and abdominal fullness with visual analogue scales [VAS; 
cutoﬀ   3·0 on a ten-point scale], and presence of diarrhoea 
as assessed by the patient [at days 5, 10, 14, 21, 28, and 35]). 
Per patient, the percentage intake of the study product or 
placebo was calculated and categorised as less than 80%, 
80–89%, 90–95%, and over 95%. Microbiological data of 
the initial positive culture for each of the infectious 
complications of the primary endpoint were collected.
Organ failure was deﬁ  ned as PaO2 below 60 mm Hg 
despite FIO2 of 30% or the need for mechanical ventilation 
(pulmonary insuﬃ     ciency), serum creatinine over 
177 mmol/L after rehydration or need for haemoﬁ  ltration 
or haemodialysis (renal failure), and systolic blood pressure 
below 90 mm Hg despite adequate ﬂ  uid resuscitation or 
need for vasopressor (mainly noradrenalin and dopamine) 
support (cardiocirculatory insuﬃ   ciency), adapted from the 
Atlanta classiﬁ  cation.
23 Multiorgan failure was deﬁ  ned as 
failure of at least two organ systems on the same day. 
Organ failure before randomisation was deﬁ  ned as any 
organ failure that started before the day of randomisation. 
Because the administration of the study product or placebo 
could start at any time during the day of randomisation, 
start of organ failure on that day was left out of this 
deﬁ  nition. Onset of organ failure after randomisation was 
deﬁ  ned as initial (for the ﬁ  rst time) onset of organ failure 
after the day of randomisation.
Data collection was done by local physicians, who 
completed case record forms. During the study an 
independent data monitor checked at least 10% of the 
individual patients’ data against the primary source data, 
on site in the participating centres. After completion of the 
follow-up of the last patient but before any analysis or 
unblinding, two authors (MGHB and HCvS) checked all 
primary and secondary endpoints on site with primary 
source data. Before any analysis and without knowledge of 
treatment allocation, the blinded adjudication committee 
judged all exclusions, endpoints that were not fully 
speciﬁ  ed in the protocol in individual patients, and serious 
adverse events. Only after agreement was reached on all 
endpoints were analyses done with blinding of the products 
administered preserved. After the results of the blinded 
analyses were presented to the monitoring committee, the 
randomisation code was broken on Oct 26, 2007.
Panel: Deﬁ  nitions included in the primary endpoint
Infected pancreatic necrosis—positive culture of peripancreatic ﬂ  uid or pancreatic necrosis 
obtained by either ﬁ  ne-needle aspiration, during the ﬁ  rst percutaneous drainage, or 
during the ﬁ  rst surgical intervention
Bacteraemia—positive blood culture. For non-pathogens (eg, coagulase-negative 
staphylococci) at least two samples had to be positive
Pneumonia—coughing, dyspnoea, chest ﬁ  lm showing inﬁ  ltrative abnormalities, lowered 
arterial blood gas with positive sputum culture. If in intensive care, a positive 
endotracheal culture is mandatory
Urosepsis*—dysuria with bacteraemia on the same day, without a urinary catheter in situ
Infected ascites†—bacteria detected in aspirate of intraperitoneal ﬂ  uid or abdominal ﬂ  uid 
sampled during surgical exploration
*Before any analysis, the adjudication committee restricted the deﬁ  nition of urinary tract infection to urosepsis. †Before any 
analysis, the adjudication committee added this group of infections to the infectious complications endpoint.
732 patients with acute pancreatitis
assessed for eligibility
298 patients with predicted severe
acute pancreatitis randomised to
treatment
434 patients excluded
323 predicted mild pancreatitis
89 predicted severe, >72 h*
7 predicted severe, excluded by
treating physician, various reasons
15 predicted severe, no consent
153 patients assigned to probiotics
(1 did not receive any study drug
because of rapid clinical deterioration,
included in the analysis)
145 patients assigned to placebo
(all received study drug)
2 patients discontinued study drug
(2 no speciﬁed reason)
0 lost to follow-up
1 patient violated inclusion criteria
(1 excluded from analysis because of
incorrect diagnosis of pancreatitis)
5 patients discontinued study drug
(3 for abdominal complaints,
1 poor taste, 1 no speciﬁed reason)
0 lost to follow-up
2 patients violated inclusion criteria
(1 wrong calculation of prediction score,
included in analysis, 1 excluded from
analysis because of incorrect diagnosis
of pancreatitis)
152 analysed 144 analysed
Figure 1: Trial proﬁ  le
*Not randomised because of clinical symptoms of pancreatitis for more than 72 h at time of diagnosis of predicted 
severe acute pancreatitis. Patients were either initially missed for randomisation, were transferred from other 
hospitals more than 72 h after onset of symptoms, or already had complaints for more than 72 h on admission.Articles
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Statistical analysis
We calculated that 200 patients with predicted severe acute 
pancreatitis would be required to detect a 20% reduction in 
the absolute risk of the occurrence of infectious 
complications (from 50% to 30% of patients during 
admission and 90-day follow-up) for the study to attain an 
80% statistical power, at a two-sided α of 0·05. This sample 
size calculation took into account the fact that up to 40% of 
patients with predicted severe pancreatitis are ultimately 
diagnosed with mild pancreatitis (ie, no local or systemic 
complications) and thus do not progress to severe or 
necrotising pancreatitis. After the ﬁ  rst 100 patients were 
randomised and had completed follow-up, the number of 
infectious complications was calculated in the total group 
of randomised patients without unblinding the data. The 
rate of infectious complications was lower than 
expected (28%), so the monitoring committee advised 
increasing the total sample size from 200 to 296 patients to 
maintain statistical power. After 184 patients had been 
randomised and had completed follow-up, a blinded 
interim analysis was done for the primary endpoint and 
mortality. Although a non-signiﬁ  cant  diﬀ  erence  in 
mortality was observed (p=0·10), the monitoring committee 
concluded that this had been caused by skewed 
randomisation because more patients in the group with 
higher mortality required admission to intensive care 
within 72 h after admission (p=0·15), whereas the overall 
mortality was well within the expected range (11%). 
According to the predeﬁ  ned stopping rule
16 the monitoring 
committee recommended that the study should be 
completed.
All data analyses were done in accordance with a 
pre-established analysis plan. The incidence of the primary 
endpoint was compared between the groups and the 
results are presented as relative risk with exact 95% CI. 
The Kolmogorov-Smirnov test was used to assess whether 
continuous data were normally distributed (p>0·05). For 
continuous variables, diﬀ   erences between groups were 
tested with Student’s t test for normally distributed data or 
Mann-Whitney U test for non-normally distributed data. 
Fisher’s exact test was used for proportions in all cases. In 
cases of signiﬁ  cant diﬀ  erence in the incidence of either the 
primary endpoint or mortality between groups, 
Kaplan-Meier curves with log-rank tests were generated.
All analyses were done on the basis of the intention-to-treat 
principle. Prespeciﬁ  ed subgroup analyses were done for 
cause of pancreatitis and for presence of pancreatic 
parenchymal necrosis. We used logistic regression models 
to do a formal test for interaction to assess whether 
treatment eﬀ  ects  diﬀ  ered  signiﬁ  cantly  between  these 
subgroups. A two-sided p value of less than 0·05 was 
deemed to be statistically signiﬁ  cant. All statistical analyses 
were done with SPSS (version 12.0.1).
Role of the funding source
The sponsor of the study had no role in the study design, 
data collection, data analysis, interpretation of the study 
results, or writing of the manuscript. The corresponding 
author had full access to all the data and coordinated the 
decision to submit for publication.
Results
732 consecutive patients with a ﬁ   rst episode of acute 
pancreatitis were registered prospectively between 
March, 2004, and March, 2007 (ﬁ  gure 1). 298 patients were 
predicted to have a severe disease course (135 patients with 
APACHE II score ≥8, 204 with Imrie score ≥3, 252 with 
C-reactive protein >150 mg/L), and were randomly 
assigned treatment with probiotics or with placebo 
(ﬁ   gure 1). Two patients—one in each group—were 
excluded from the ﬁ  nal analysis because of an incorrect 
Probiotics (N=152) Placebo (N=144)
Age (years) 60·4 (16·5) 59·0 (15·5)
Sex (male)  91 (60%) 83 (58%)
Body-mass index (kg/m
2) 27·1 (6·1) 27·8 (5·9)
Cause of pancreatitis 
Biliary 92 (61%) 75 (52%)
Alcohol 27 (18%) 28 (19%)
Unknown 21 (14%) 28 (19%)
Medication 4 (3%) 6 (4%)
Hypertriglyceridaemia 4 (3%) 3 (2%)
Other 4 (3%) 4 (3%)
American Society of Anaesthesiologists class
I (healthy status) 62 (41%) 62 (43%)
II (mild systemic disease) 76 (50%) 64 (44%)
III (severe systemic disease) 14 (9%) 18 (13%)
Severity of pancreatitis 
APACHE II score* 8·6 (4·4) 8·4 (4·5)
Imrie score
 (ﬁ  rst 48 h) 3·3 (1·7) 3·4 (1·6)
C-reactive protein concentration (mg/L) (highest 
ﬁ  rst 48 h)
268 (127) 270 (122)
SOFA score (on admission) 2·1 (2·0) 1·9 (1·6)
MODS (on admission) 1·6 (1·6) 1·5 (1·5)
Organ failure before randomisation* 9 (6%) 5 (3%)
Multiorgan failure before randomisation  5 (3%) 1 (0·7%)
Endoscopic sphincterotomy 48 (32%) 35 (24%)
Time from ﬁ  rst symptoms to admission (days) 0 (0–3) 0 (0–3)
Time from admission to ﬁ  rst dose (days) 2 (0–4) 2 (0–3)
Time from admission to enteral nutrition (days) 2 (0–7) 2 (0–7)
Contrast-enhanced CT 
Necrotising pancreatitis† 46 (30%) 34 (24%)
≤30% pancreatic parenchymal necrosis 16 (11%) 14 (10%)
>30% pancreatic parenchymal necrosis 30 (20%) 20 (14%)
No contrast-enhanced CT done 6 (4%) 12 (8%)
CT severity index‡ 4 (0–10) 4 (0–10)
Data are n (%), mean (SD), or median (range). APACHE II=Acute Physiology and Chronic Health Evaluation score, 
determined on admission. MODS=multiple organ dysfunction score (range 0–24, higher scores indicating more severe 
disease). SOFA=sequential organ failure assessment (range 0–24, higher scores indicating more severe disease). 
*Patients with multiorgan failure are included in the group patients with organ failure. †Done on day 7–10 after 
admission. ‡CT severity index ranges from 0 to 10, higher scores indicating more extensive pancreatic parenchymal 
necrosis and peripancreatic ﬂ  uid collections.
Table 1: Baseline characteristicsArticles
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diagnosis of acute pancreatitis; one was ultimately 
diagnosed with acute cholecystitis and the other with 
post-pancreatic surgery anastomotic leakage. One patient 
who did not receive any study product and one who, in 
retrospect, had predicted mild pancreatitis were included 
in the ﬁ   nal analysis (ﬁ   gure 1). Study groups were 
comparable for all baseline characteristics (table 1).
All but ﬁ  ve patients started treatment within 72 h of 
onset of symptoms. Median intake of probiotics or placebo 
per patient was 100% (25% lower limit 91%). No diﬀ  erence 
in the categorised percentage intake between the groups 
was found (data not shown; p=0·78). No infections were 
conﬁ  rmed to be caused by any of the probiotic strains 
administered. During the study, two serious adverse events 
were reported; both patients died. The monitoring 
committee convened on both occasions: in one patient, a 
ruptured caecum with ischaemia was found during 
emergency laparotomy and the second patient had 
small-bowel ischaemia diagnosed at emergency laparotomy. 
In both cases, the randomisation code was broken (both 
patients had received probiotics). This information was 
revealed only to members of the monitoring and steering 
committees. A review of published work did not reveal any 
evidence of a relation between bowel ischaemia and the 
use of probiotics. The monitoring committee subsequently 
advised that the study continue. The institutional review 
board was informed on both occasions.
There was no signiﬁ  cant diﬀ  erence in the occurrence of 
the composite primary endpoint between the two groups, 
nor were there any signiﬁ  cant diﬀ  erences between the 
groups in its individual components (table 2). The relative 
risk for the primary endpoint was 1·06 (95% CI 0·75–1·51). 
Table 3 shows the pathogens cultured from the 87 patients 
with an infectious complication; no signiﬁ  cant diﬀ  erences 
between the groups were observed.
There were signiﬁ  cantly more deaths in the probiotics 
group than there were in the placebo group (p=0·01; table 2 
and ﬁ   gure 2); the relative risk for mortality was 2·53 
(95% CI 1·22–5·25). Most of the deaths were caused by 
multiorgan failure: 20 (83%) of those in the probiotics 
group and seven (78%) of those in the placebo group. 
Other causes of death were respiratory failure after 
aspiration (one) and cerebral infarction/bleeding (three) in 
the probiotics group, and ruptured aneurysm (one) and 
cerebral infarction (one) in the placebo group.
Bowel ischaemia was detected during operation or 
autopsy in nine patients in the probiotics group; eight of 
these patients died as a result. No cases of bowel ischaemia 
were seen in the placebo group (p=0·004 for diﬀ  erence 
between groups; table 4). The nine cases of bowel ischaemia 
were all diagnosed within the ﬁ  rst 14 days of admission in 
seven diﬀ  erent hospitals; four university and three teaching 
hospitals. In all nine patients, contrast-enhanced CT (either 
the baseline CT or an earlier CT) showed unequivocal 
evidence of acute pancreatitis. All these patients had early 
onset of organ failure (median 2 days after admission, 
range 1–6 days). At the time of diagnosis of bowel 
ischaemia, six patients had vasopressor support (14 patients 
in the placebo group and 23 in the probiotics group had 
vasopressor support in the ﬁ   rst 14 days). Patients had 
received a median of six doses of probiotics (range 
4–22 doses) before diagnosis of bowel ischaemia. The 
small bowel was involved in eight of the nine patients 
(including the survivor). During autopsy (six patients), ﬁ  ve 
patients with small-bowel ischaemia had no sign of 
occlusive disease in the mesenteric vessels.
Apart from the patients with bowel ischaemia, 11 patients 
died in the 2 weeks after admission: eight in the probiotics 
group and three in the placebo group. These patients died 
of multiorgan failure without signs of bowel ischaemia.
No signiﬁ  cant  diﬀ   erences were noted between the 
groups for the serial SOFA scores (data not shown). 
Although more patients in the probiotics group than in the 
placebo group developed organ failure during the study 
there was no diﬀ  erence between the groups with regard to 
organ failure that started after the day of 
randomisation (p=0·6). During the study, 102 (34%) patients 
developed the most severe form of acute pancreatitis 
(organ failure or pancreatic parenchymal necrosis); 
56 (37%) in the probiotics group and 46 (32%) in the 
Probiotics (N=152) Placebo (N=144) p value
Primary endpoint 
Any infectious complication*  46 (30%) 41 (28%) 0·80
Infected necrosis 21 (14%) 14 (10%) 0·29
Bacteraemia 33 (22%) 22 (15%) 0·18
Pneumonia 24 (16%) 16 (11%) 0·31
Urosepsis 1 (0·7%) 2 (1%) 0·61
Infected ascites 4 (3%) 0 (0%) 0·12
Secondary endpoint 
Use of antibiotics, any indication 75 (49%) 76 (53%) 0·56
Percutaneous drainage 14 (9%) 8 (6%) 0·23
Surgical intervention, any indication 28 (18%) 14 (10%) 0·05
Necrosectomy 24 (16%) 14 (10%) 0·16
Intensive care admission 47 (31%) 34 (24%) 0·19
Intensive care stay (days) 6·6 (17·1) 3·0 (9·3) 0·08
Hospital stay (days) 28·9 (41·5) 23·5 (25·9) 0·98
Organ failure during admission, any onset†‡ 41 (27%) 23 (16%) 0·02
Multiorgan failure during admission, any onset‡ 33 (22%) 15 (10%) 0·01
Organ failure, onset after randomisation†§ 21 (14%) 16 (11%) 0·60
Multiorgan failure, onset after randomisation§ 18 (12%) 11 (8%) 0·25
Nausea 20 (13%) 23 (16%) 0·51
Abdominal fullness 36 (24%) 43 (30%) 0·24
Diarrhoea 25 (16%) 28 (19%) 0·55
Bowel ischaemia 9 (6%) 0 (0%) 0·004
Mortality 24 (16%) 9 (6%) 0·01
Data are mean (SD) or n (%). *Patients with one or more infectious complication. †Patients with multiorgan failure are 
included in the organ failure group. ‡Patients with organ failure present at any time during admission, irrespective of 
the date of onset of organ failure, are included. §Patients in whom organ failure developed (for the ﬁ  rst time) after the 
day of randomisation are included. Patients in whom organ failure (in any organ) started before the day of 
randomisation or on the day of randomisation are not included.
Table 2: EndpointsArticles
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placebo group. 18 patients did not undergo a CT: the 
treating physician deemed CT unnecessary in 17 patients, 
or the patient refused because of good clinical condition; 
one patient in the placebo group died on day 4 before CT 
could be done. The latest point at which a baseline CT was 
done was 10 days after admission.
Predeﬁ  ned subgroup analyses were done for the presence 
of pancreatic parenchymal necrosis (any extent) and cause 
(biliary vs non-biliary) for both the primary endpoint and 
mortality. The tests for interaction were not signiﬁ  cant—
ie, we could not conﬁ  rm an interaction between probiotic 
administration and pancreatic necrosis or underlying 
cause for either the primary endpoint or for mortality. In 
the subgroup of patients with pancreatic parenchymal 
necrosis, one or more infectious complication consistent 
with the primary endpoint occurred in 32 (70%) of 
46 patients in the probiotics group versus 18 (53%) of 
34 patients in the placebo group (p=0·16). In patients with 
pancreatic parenchymal necrosis, 19 (41%) of 46 patients in 
the probiotics group died, compared with ﬁ  ve (15%) of 34 
in the placebo group (p=0·01).
Discussion
This randomised, double-blind, placebo-controlled trial in 
patients with predicted severe acute pancreatitis showed 
no beneﬁ  cial  eﬀ   ect of probiotic prophylaxis on the 
occurrence of infectious complications. However, mortality 
in the probiotics group was about twice as high as in the 
placebo group. Thus, this combination of probiotics should 
not be administered routinely in patients with predicted 
severe acute pancreatitis, and such preparations can no 
longer be considered to be harmless adjuncts to enteral 
nutrition. 
The rate of infectious complications in our study is in 
line with a large German multicentre study (31%) on 
antibiotic prophylaxis in predicted severe acute pancreatitis.
8 
Although antibiotic prophylaxis was strongly discouraged 
in our study, antibiotics were used in about half the 
patients, although only a third of all patients had a 
documented infection. Antibiotics were sometimes started 
pre-emptively, on the basis of clinical suspicion of infection 
before bacterial culture results becoming available. 
Obviously, this clinical indication for antibiotic treatment 
leads to false-positive diagnoses of infectious complications. 
The overall rate of antibiotic use in our study was no 
diﬀ   erent from that in the placebo groups of trials of 
antibiotic prophylaxis in acute pancreatitis.
7,8
The adverse eﬀ   ects of probiotics noted here were 
unexpected. Several studies have associated probiotics with 
a reduction in infectious complications.
13,14 Most of these 
studies have been done in patients undergoing elective 
abdominal operations. However, one randomised study in 
90 critically ill patients showed a non-signiﬁ  cant increase 
in septic complications in the probiotics group;
24 another 
randomised study in 61 children admitted to a paediatric 
intensive-care unit was discontinued prematurely because 
of a non-signiﬁ  cant increase in infections in the probiotics 
Probiotics 
(N=152)
Placebo 
(N=144)
Gram-positive bacteria
Staphylococcus spp 20 20
Staphylococcus aureus 10 11
Coagulase-negative staphylococci 9 5
Enterococcus spp 10 3
Streptococcus spp 33
Other gram-positive microorganisms† 3 3
Gram-negative bacteria
Enterobacteriaceae 28 20
Escherichia coli 17 7
Klebsiella spp 88
Other gram-negative microorganisms‡ 4 8
Fungi
Candida spp  51
Chrysosporium sp 10
Unknown 0 1
*Only the ﬁ  rst positive culture result of each infection consistent with the primary 
endpoint was used. If, in one patient, diﬀ  erent organisms were cultured from 
diﬀ  erent sites (eg, from the initial positive blood culture and from pancreatic 
necrosis) these are all listed. If, in one patient, the same organism was cultured 
from diﬀ  erent sites, this organism was listed only once. †Bacillus spp (2), 
Clostridium sp (1), Corynebacterium striatum (1), Propionibacterium sp (1), and 
unknown (1). ‡Aeromonas spp (1), Bacteroides spp (2), Moraxella catarrhalis (1), 
Neisseria meningitidis (2), Pasteurella multocida (1), Pseudomonas auruginosa (1), 
Stenotrophomonas maltophilia (3), and Veillonella sp (1).
Table 3: Pathogens isolated from 87 patients with an infectious 
complication*
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Figure 2: Kaplan–Meier time-to-event analysis for mortality in the ﬁ  rst 90 days after randomisation
A follow-up of longer than 90 days was obtained in 266 (90%) patients. Three deaths occurred after 90 days: 
two in the probiotics group (day 112 and 125) and one in the placebo group (day 140).Articles
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group.
25,26 To date, the main criticism of most randomised 
controlled trials of probiotic prophylaxis is methodological 
shortcomings—eg, analyses not done by intention to treat 
and sample sizes too small to provide convincing evidence 
on relevant clinical endpoints.
Two small placebo-controlled randomised controlled 
trials of probiotic prophylaxis have been done in patients 
with acute pancreatitis. The ﬁ   rst study randomised 
45 patients with both predicted mild and predicted severe 
pancreatitis of solely non-biliary causes.
15 The infection 
rate was lower in the probiotics group than in the placebo 
group; no eﬀ  ect on mortality was noted. However, this 
study was criticised because patients with biliary pan-
creatitis were excluded, the sample size was small, and 
analyses were not by intention to treat.
27,28 In the second 
trial, done by the same research group in 62 patients with 
predicted severe pancreatitis, the diﬀ  erence in the rate of 
infectious complications seen in the ﬁ  rst trial could not 
be reproduced.
29 This second study used a probiotic 
prepar  ation previously found to be eﬀ  ective in preventing 
infectious complications in patients undergoing 
abdominal operations.
13,14
Because the ﬁ  ndings of our trial are in marked contrast 
with the previous reports, we scrutinised our results and 
methodology for explanations other than a deleterious 
eﬀ  ect of probiotics. Randomisation was successful, since 
there were no signiﬁ  cant diﬀ  erences in baseline charac-
teristics between groups. In the probiotics group there was 
a (non-signiﬁ   cantly) higher proportion of patients with 
organ failure before randomisation as well as a greater 
proportion of patients with more than 30% pancreatic 
parenchymal necrosis than in the placebo group. When we 
assessed this imbalance by use of logistic regression, the 
(adjusted) mortality remained signiﬁ  cantly higher in the 
probiotics group than in the placebo group (data not 
shown). There was no indication that treatment eﬀ  ects 
diﬀ   ered in the subgroup analyses. We also considered 
whether the composition of the product or the doses used 
explained the eﬀ  ects noted. The daily dose was similar to 
doses used in previous studies and, although the com-
bination of probiotic strains administered was diﬀ  erent 
from the preparations used so far, the individual strains 
have an unblemished reputation as probiotics, both in 
(smaller) clinical studies and in daily practice in the food 
industry. The six probiotic strains used in this study were 
selected from 69 diﬀ  erent probiotic bacteria on the basis of 
their capacity to inhibit growth of gut-derived pathogens 
and to modulate immune responses.
20 The combination of 
strains was shown to result in a better antimicrobial 
spectrum, induction of interleukin 10, and silencing of 
pro-inﬂ   ammatory cytokines than the individual com-
ponents.
20 The combination of strains was found capable of 
inhibiting the in-vitro growth of a wide variety of pathogens 
cultured from pancreatic necrosis.
21 Again, the combination 
of strains had better growth-inhibiting capacities than did 
the individual strains.
21 Additionally, when the preparation 
was administered before induction of severe acute 
pancreatitis in rats, a signiﬁ  cant reduction of both infectious 
complications and late mortality was noted.
30 The same 
preparation was also used in three small clinical studies 
under elective circumstances in healthy volunteers, patients 
with ileostomy, patients about to undergo pan  cre  atico-
duodenectomy, and patients with pri  mary sclerosing 
cholangitis, and no adverse events were noted (unpublished 
data, trial registry ISRCTN45167712, ISRCTN71637623, and 
NCT00161148). However, these patients were less ill than 
the patients in the present study.
Previous randomised trials with probiotics have been of 
much smaller sample size and with fewer critically ill 
patients than in the present study. Consequently, the power 
SSN Sex Age 
(years)
Day of 
diagnosis
Days of treatment 
before diagnosis
Vasopressor support 
at day of diagnosis
Day of onset of 
organ failure
Day of 
death
Findings
Patient 10 Female 40 5 3 0 1 5 Emergency laparotomy day 5: perforated caecum with adjacent 
ischaemia. At autopsy: mucosal ischaemia 80 cm of small bowel
Patient 93 Male 61 12 11 0 1 13 Emergency laparotomy day 12: resection of 50 cm ischaemic 
proximal jejunum. At autopsy: necrosis and inﬂ  ammatory changes of 
the small bowel wall
Patient 121 Male 62 4 2 1 2 4 At autopsy: only the proximal jejunum vital, rest of the small bowel 
ischaemic
Patient 124 Female 88 6 4 1 6 6 At autopsy: inﬂ  ammatory changes of the duodenum wall and 
necrotising oesophagitis
Patient 160 Female 62 4 2 1 1 4 Emergency laparotomy day 4: ischaemia of most of the small bowel
Patient 202 Male 60 12 10 1 2 26 Emergency laparotomy day 12: necrosis of 40 cm jejunum. At 
autopsy: necrotising jejunitis
Patient 235 Male 57 9 9 1 2 125 Emergency laparotomy day 9: resection of 90 cm of ischaemic ileum. 
Patient died 4 months later from cerebral infarction
Patient 243 Male 22 4 3 0 2 Survived Emergency laparotomy day 4: ischaemic proxmial jejunum
Patient 297 Male 57 3 3 1 2 6 Emergency laparotomy day 3: ischaemia and inﬂ  ammation of the 
entire small and large bowel
SSN=sequential study number, patient number 1 was the ﬁ  rst patient in the trial.
Table 4: Clinical characteristics of nine patients with bowel ischaemia in the probiotics groupArticles
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of these studies was too small to detect diﬀ  erences in 
mortality or uncommon adverse events such as bowel 
ischaemia. In our study, probiotics caused a signiﬁ  cant 
increase in mortality, most likely a result of deleterious 
eﬀ  ects on the (small) bowel wall. After administration of 
probiotics, no signiﬁ   cant increase in new onset organ 
failure was seen. Possibly, probiotics especially exert their 
adverse eﬀ   ects in patients in whom organ failure has 
already occurred. Because the exact mechanism causing 
the bowel ischaemia seen here is, at present, unknown, we 
cannot exclude or conﬁ  rm that another product—eg, a 
combination of strains or one strain alone—would have 
resulted in similar results. However, in view of the fatal 
nature of these complications, the administration of any 
type of probiotic in this category of patients must strongly 
be advised against until the mechanism of the complications 
has been unravelled.
The occurrence of non-occlusive mesenteric ischaemia 
is well known in critically ill patients,
31 and several cases of 
non-occlusive mesenteric ischaemia have been reported in 
acute pancreatitis.
32 Such complications could explain why 
only two of the nine cases of mesenteric ischaemia seen in 
this study were reported as a serious adverse event. 
Evidence exists to suggest that intestinal bloodﬂ  ow at the 
mucosal level is generally reduced in acute pancreatitis. 
An experimental study in rats found a reduction in 
bloodﬂ  ow to the intestinal mucosa of up to 85%.
33 A clinical 
study in patients with severe pancreatitis showed a 
signiﬁ  cant increase in a biological marker for enterocyte 
death and small-bowel ischaemia.
34 In a severely ill patient 
going through a phase of severe systemic inﬂ  ammation or 
organ failure, an already critically reduced bloodﬂ  ow and 
oxygen supply in the small-bowel mucosa might be further 
compromised by the administration of enteral feeding, 
known for its increased demand for local oxygen.
35,36 This 
eﬀ  ect is probably local, since ischaemia usually occurs at 
the site of administration of enteral feeding.
35,36 However, 
until now, this occurrence has not been recognised as an 
argument to refrain from enteral nutrition in critically ill 
patients because the beneﬁ  cial eﬀ  ects outweigh the small 
risk of developing ischaemia.
We can only speculate as to the mechanism of bowel 
ischaemia in the probiotics group. The administration of 
10
 billion probiotic bacteria per day on top of enteral 
nutrition might have even further increased local oxygen 
demand, with a combined deleterious eﬀ  ect on an already 
critically reduced bloodﬂ  ow. A second possible explanation 
could be that the presence of probiotics caused local 
inﬂ  ammation at the mucosal level. Experimental studies 
have shown that gut epithelial cells under metabolic stress 
react to commensal bacteria with an inﬂ  ammatory 
response.
37 One could postulate that increasing the bacterial 
load in the small bowel could lead to aggravation of local 
inﬂ  ammation, again with a further reduction of capillary 
bloodﬂ  ow and ultimately ischaemia. Notably, three of the 
six autopsy reports of patients with bowel ischaemia 
mentioned inﬂ  ammatory changes of the small-bowel wall.
A speculative parallel with immunonutrition can be 
drawn from a recent meta-analysis showing that 
although immunonutrition in elective surgical patients 
reduced the infection rate, it increased mortality in 
critically ill patients.
38 This eﬀ   ect was seen only in 
studies of high methodological quality and the reasons 
for the increased mortality could not be identiﬁ  ed. 
Experimental studies in rats showed that pretreatment 
with glutamine protects against the eﬀ  ects of bowel 
ischaemia,
39 whereas mortality increased when 
glutamine was administered after the induction of a low 
ﬂ  ow  state.
40 Apparently, there is reason for concern 
about administration of potent immuno  nutritional 
supplements in the presence of a low ﬂ  ow state, or more 
generally, in the critically ill.
Our ﬁ  ndings show that probiotics should not be ad-
ministered routinely in patients with predicted severe 
acute pancreatitis, and that the particular composition 
used here should be banned for the present indication. 
Whether other (combinations of) strains might have 
resulted in diﬀ  erent results is debatable, but, until the 
under lying mechanism is actually revealed, administration 
of probiotics in patients with predicted severe acute pan-
creatitis must be regarded as unsafe. Most importantly, 
probiotics can no longer be considered to be harmless ad-
juncts to enteral nutrition, especially in critically ill patients 
or patients at risk for non-occlusive mesenteric 
ischaemia.
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